RUcore Resource Object
RUcore Resource Object
PDF-1(2.63 MB)
TitleNon-Invasive Glucose Monitoring: A Novel Approach
PublisherDiabetes Technology Society
NameHarman-Boehm, Ilana (Author), Gal, Avner (Author), Raykhman, Alexander M. (Author), Zahn, Jeffrey D. (Author), Naidis, Eugene (Author), Mayzel, Yulia (Author),
Date Created2009
Subjectnoninvasive glucose monitoring,
self-monitoring of blood glucose,
ear clip,
combination methodology,
Patient self-monitoring,
Blood sugar monitoring,
Diagnosis, Noninvasive
DescriptionBackground: The main concern in noninvasive (NI) glucose measurement is achieving high accuracy readings, although no blood (or other fluid) is involved in the process. Using methods based on different physical properties of a measured object can ensure the independence of each of the readings and therefore improve the validity of the end result. By using a combination of (three) independent technologies—ultrasonic, electromagnetic, and thermal—GlucoTrack™ presents a unique approach for a real-time, truly NI blood glucose spot measurement.
Methods: Clinical trials were performed in two stages. Stage 1 was an initial method validation and performance verification of the device. In this stage, 50 type 1 and 2 diabetic patients, as well as healthy subjects, were evaluated with GlucoTrack against Ascensia Elite® (Bayer). In the second stage, 85 additional diabetic subjects were evaluated in half and full daytime sessions using a GlucoTrack comparison with HemoCue® (Glucose 201+).
Results: A total of 135 subjects were tested during the trial period, producing 793 data pairs. Using Clarke error grid analysis, 92% of the readings fell in the clinically acceptable zones A and B, with 50% in the A zone. Mean and median relative absolute differences were 29.9 and 19.9%, respectively.
Conclusions: Integrating several modalities for NI assessment of glucose level enables more accurate readings, while a possible aberration in one modality is bypassed by the others. The present generation of GlucoTrack gives promising results; however, further improvement of the accuracy of the device is needed.
Methods: Clinical trials were performed in two stages. Stage 1 was an initial method validation and performance verification of the device. In this stage, 50 type 1 and 2 diabetic patients, as well as healthy subjects, were evaluated with GlucoTrack against Ascensia Elite® (Bayer). In the second stage, 85 additional diabetic subjects were evaluated in half and full daytime sessions using a GlucoTrack comparison with HemoCue® (Glucose 201+).
Results: A total of 135 subjects were tested during the trial period, producing 793 data pairs. Using Clarke error grid analysis, 92% of the readings fell in the clinically acceptable zones A and B, with 50% in the A zone. Mean and median relative absolute differences were 29.9 and 19.9%, respectively.
Conclusions: Integrating several modalities for NI assessment of glucose level enables more accurate readings, while a possible aberration in one modality is bypassed by the others. The present generation of GlucoTrack gives promising results; however, further improvement of the accuracy of the device is needed.
NoteThe published version of this article is available at http://www.journalofdst.org/amember/plugins/protect/new_rewrite/login.php?v=-any&url=/March2009/Articles/VOL-3-2-SYM4-HARMAN-BOEHM.pdf%3f
NoteJ Diabetes Sci Technol 2009;3(2):253-260.
Genrearticles
Persistent URLhttp://hdl.rutgers.edu/1782.2/rucore30101200001.Manuscript.000050454
LanguageEnglish
CollectionZahn Jeffrey Collection
Organization NameRutgers, The State University of New Jersey
RightsCopyright for scholarly resources published in RUcore is retained by the copyright holder. By virtue of its appearance in this open access medium, you are free to use this resource, with proper attribution, in educational and other non-commercial settings. Other uses, such as reproduction or republication, may require the permission of the copyright holder.